诺诚健华:CD19 单抗在中国获批上市

生物药大时代
May 22, 2025

声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。5 月 21 日,NMPA 官网显示,诺诚健华 CD19 单抗坦昔妥单抗(Tafasitamab)获批上市,用于联合来那度胺治疗不适合自体干细胞移植条件的复发/难治弥漫性大 B 细胞淋巴瘤(DLBCL)成人患者。此前该适应症曾被纳入优先审评。来源:...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10